Table 2.

Treatment-related adverse events

Ciforadenant (n = 33)Ciforadenant + atezolizumab (n = 35)
Event, number of patients, (%)Any gradeGrade 3/4Any gradeGrade 3/4
Fatigue13 (39.4)0 (0.0)16 (45.7)0 (0.0)
Pruritus7 (21.2)0 (0.0)9 (25.7)0 (0.0)
Decreased appetite4 (12.1)1 (3.0)6 (17.1)0 (0.0)
Dizziness4 (12.1)0 (0.0)1 (2.9)0 (0.0)
Nausea3 (9.1)0 (0.0)7 (20.0)1 (2.9)
Pyrexia3 (9.1)0 (0.0)1 (2.9)0 (0.0)
Anemia2 (6.1)1 (3.0)4 (11.4)0 (0.0)
Arthralgia2 (6.1)1 (3.0)5 (14.3)1 (2.9)
Chills2 (6.1)0 (0.0)1 (2.9)0 (0.0)
Cough2 (6.1)0 (0.0)3 (8.6)0 (0.0)
Diarrhea2 (6.1)0 (0.0)5 (14.3)0 (0.0)
Epistaxis2 (6.1)0 (0.0)0 (0.0)0 (0.0)
Gastroesophageal reflux2 (6.1)0 (0.0)0 (0.0)0 (0.0)
Hyperhidrosis2 (6.1)0 (0.0)1 (2.9)0 (0.0)
Hypophosphatemia2 (6.1)0 (0.0)3 (8.6)1 (2.9)
Musculoskeletal chest pain2 (6.1)0 (0.0)2 (5.7)0 (0.0)
Myalgia2 (6.1)0 (0.0)2 (5.7)0 (0.0)
Edema peripheral2 (6.1)1 (3.0)1 (2.9)0 (0.0)
Osteoarthritis2 (6.1)0 (0.0)2 (5.7)0 (0.0)
Rash2 (6.1)0 (0.0)4 (11.4)0 (0.0)
Vomiting2 (6.1)0 (0.0)4 (11.4)0 (0.0)
Abdominal pain1 (3.0)0 (0.0)3 (8.6)1 (2.9)
AST increased1 (3.0)0 (0.0)2 (5.7)1 (2.9)
Blood creatinine increased1 (3.0)0 (0.0)2 (5.7)0 (0.0)
Insomnia1 (3.0)0 (0.0)2 (5.7)0 (0.0)
Dysgeusia0 (0.0)0 (0.0)2 (5.7)0 (0.0)
  • NOTE: Adverse events with an incidence of ≥5% of any grade in any treatment category.